LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that treatment with its cancer drug candidate INNO-206 resulted in a statistically significant reduction in the average primary tumor size in an animal model of pancreatic cancer, outperforming the broadly used chemotherapeutic drug doxorubicin, as well as the current standard of care in pancreatic cancer treatment, gemcitabine.
